Photobiomodulation Therapy in Persons With Multiple Sclerosis

Persons with multiple sclerosis (MS) MS commonly experience muscle weakness and fatigue which
may contribute to the commonly reported symptomatic fatigue. Photobiomodulation therapy
(PBMT) induced with light in the visible red to near infrared (VIS/NIR) region of the
spectrum (600-1000 nm) can stimulate cytochrome c oxidase and improve mitochondrial function.
PBMT is an emerging therapeutic modality for soft tissue injury, chronic inflammation,
neurodegeneration , and retinal diseases. PBMT has also been used to enhance muscle
endurance, strength and recovery in healthy adults. We propose that in persons with MS, PBMT
will 1) enhance regional muscle endurance after acute treatment and 2) enhance functional
endurance after extended treatment. We will also test to determine if improvements are due to
central or peripheral neuromuscular or cardiovascular mechanisms. Final, we will explore if
regional PBMT can result in systemic anti-inflammatory effects.

Inclusion Criteria:

1. Relapsing remitting MS,

2. Independent or ambulatory with minimal aid.

3. Must be able to move foot (ankle dorsiflexion) at least moderately forcibly against
gravity (manual muscle test score 3-5)

4. Subjects must be able to walk for 6 minutes independently with no or minimal use of an
assistive device.

Exclusion Criteria:

1. No noticeable left right ankle strength asymmetry

2. No exacerbations (MS attacks) or immunosuppressive therapy use within the previous 6
months

3. No concurrent infection or known cardiovascular disease including having a pacemaker;
or other serious medical co-morbidity including metabolic, mitochondrial, autoimmune,
diseases or other co-existing neurologic conditions.

4. Not involved in any clinical trial or other research that could confound results.

5. Must not be pregnant

6. Must not have an active diagnosis of cancer